Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) CEO Saiid Zarrabian tells Proactive the group has reported topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083.
Zarrabian says the Phase 2 trial testing VAL-083 in glioblastoma multiforme (GBM) patients was 'encouraging' as it 'showed an 'improvement over the standard of care.'